Polar Asset Management Partners Inc. Has $328,000 Stock Holdings in NKGen Biotech, Inc. (NYSE:NKGN)

Polar Asset Management Partners Inc. reduced its holdings in shares of NKGen Biotech, Inc. (NYSE:NKGN) by 57.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 500,000 shares of the company’s stock after selling 681,872 shares during the period. Polar Asset Management Partners Inc. owned about 1.11% of NKGen Biotech worth $328,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Magnetar Financial LLC acquired a new stake in NKGen Biotech during the fourth quarter valued at approximately $175,000. Kepos Capital LP bought a new position in shares of NKGen Biotech during the 4th quarter worth approximately $151,000. Sequoia Financial Advisors LLC boosted its stake in NKGen Biotech by 126.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock valued at $102,000 after buying an additional 87,000 shares in the last quarter. Geode Capital Management LLC grew its position in NKGen Biotech by 12.8% in the fourth quarter. Geode Capital Management LLC now owns 127,168 shares of the company’s stock valued at $83,000 after acquiring an additional 14,454 shares during the period. Finally, Advisory Research Inc. acquired a new position in NKGen Biotech during the fourth quarter worth $28,000. 76.17% of the stock is currently owned by institutional investors and hedge funds.

NKGen Biotech Stock Performance

Shares of NYSE NKGN opened at $0.29 on Wednesday. NKGen Biotech, Inc. has a 52-week low of $0.10 and a 52-week high of $1.75. The business has a fifty day moving average of $0.18 and a two-hundred day moving average of $0.36. The stock has a market cap of $12.81 million, a PE ratio of -0.06 and a beta of 0.84.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.